INRG staging and risk groups
INRG staging is the international system that sorts neuroblastoma into very-low, low, intermediate and high risk using age, spread, MYCN status and tumour biology.
International Neuroblastoma Risk Group (2009): stages L1/L2 (localised, by image-defined risk factors), M (metastatic), MS (infant metastatic to skin/liver/marrow). Risk groups combine stage, age (<18 months), MYCN amplification, 11q aberration, ploidy and histology. Roughly 50% of patients are high risk; very-low-risk L1/MS may be observed and regress spontaneously.
Pages like this
not linked directly; found by shared links- TermMYCN amplification
Shares Susan L. Cohn, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TrialNaxitamab Study 201
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaGuaranteed-quality childhood cancer medicines free of charge in 50 countries
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- PersonAlexandra "Alex" Scott
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaA paediatric palliative care team in every childhood cancer unit
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TrialNMTRC003/003B (DFMO maintenance)
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.